medigraphic.com
Patología Revista Latinoamericana

2012, Número 3

<< Anterior Siguiente >>

Patol Rev Latinoam 2012; 50 (3)


Restricción de crecimiento intrauterino idiopático con hallazgos trombóticos en placenta: reporte de caso y revisión de la literatura

Espinosa MA, Olaya CM, García-Robles R, Bermúdez M

Idioma: Español
Referencias bibliográficas: 55
Paginas: 214-219
Archivo PDF: 119.51 Kb.


RESUMEN

La restricción de crecimiento intrauterino representa un problema de salud pública en Colombia debido a sus altas tasas de morbilidad y mortalidad. Se considera una entidad multifactorial aunque en gran parte de los casos no se encuentra causa aparente. Las alteraciones de los factores de coagulación y de los anticoagulantes naturales encontrados en pacientes con trombofilias congénitas y adquiridas se consideran factores fisiopatológicos importantes en el desarrollo de la restricción del crecimiento intrauterino; aún en aquellos casos denominados idiopáticos. Dichas alteraciones de la coagulación potencian el efecto protrombótico del embarazo y generan cambios placentarios asociados con hipoxia como el aumento de los depósitos de fibrina, los infartos extensos, los trombos oclusivos de vasos coriales y la arteriopatía decidual.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Mayhew T, Ohadikea C, Bakerb PN, Crockerb IP, Mitchellc C, Ongc SS. Stereological Investigation of Placental Morphology in Pregnancies Complicated by Pre-eclampsia with and without Intrauterine Growth Restriction. plac. 2002;24: pp. 1830-1833.

  2. Many, A, Schreiber L, Rosner S, Lessing JB, Eldor A, Kupferminc MJ. Pathologic Features of the Placenta in Women With Severe Pregnancy Complications and Thrombophilia. Obstet Gynecol 2001;98(6):1041-1044.

  3. Bamberg C, Kalache K. Prenatal diagnosis of fetal growth restriction. Semin Fetal Neonatal Med 2004;9(5):387-394.

  4. Mamelle N, Boniol M, Rivière O, Joly MO . Georges Mellier, Maria B, et al. Identification of newborns with Fetal Growth Restriction (FGR) in weight and/or length based on constitutional growth potential. Eur J Pediatr 2006;165(9):717–725.

  5. Maulik, D. Fetal Growth Restriction: The Etiology. Clin Obstet Gynecol 2006;49(2):228-235.

  6. Vedmedoska N, Dace R, Uldis T, Jana Z, Gilbert D. Preventable Maternal Risk Factors and Association of Genital Infection with Fetal Growth Restriction. Gynecol Obstet Invest 2010;70(4):291–298.

  7. Jamal A, Hantoshzadeh S, Hekmat H, Abbasi S. The Association of Thrombophilia with Fetal Growth Restriction. Arch Iran Med 2010;13(6):482-485.

  8. Greer I. Thrombophilia: implications for pregnancy outcome. Thromb Res 2003;109:73–81.

  9. Robertson L, Wu O, Langhome P, Twaddle S, Clark P, Lowe GD, et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006;132(2):171-196.

  10. Merviel P, Lourdel E, Cabry R, Boulard V, Brzakowski M, Demailly P, et al. Physiopathology of human embryonic implantation: clinical incidences; Folia Histochem Cytobiol 2009;49(5):824-834.

  11. Pileri P, Franchi F, Cetin I, Chiara M, Antonazzo P, Ibrahim B. Maternal and Fetal Thrombophilia in Intrauterine Growth Restriction in the Presence or Absence of Maternal Hypertensive Disease. Reprod Sci 2010;17(9):844-848.

  12. Castelluci M. Basic structure of the villous tree. En: Castelluci M, editor. Pathology of the Human Placenta. 3rd Edition. Springer Verlag; 1995. pp. 94-95.

  13. González-Gross M, Sola R, Castillo M. Folato una vitamina milagrosa. Med Clin (Barc) 2002;119(16):627-35.

  14. Stabler S, Allen R. Vitamin B12 deficiency as a worldwide problem. Annu Rev Nutr 2004;24:299–326.

  15. Lopez de Quezada E, Villaseca M, Lailla M. Plasma total homocysteine in uncomplicated pregnancy and in preeclampsia. Eur J Obstet Gynecol Reprod Biol 2003;108:45–49.

  16. Vélez Gómez MP, Barros F, Echevarria-Restrepo LG, Hormanza-Angel MP. Prevalencia de bajo peso al nacer y factores maternos asociados: Unidad de Atención y Protección Materno Infantil de la Clínica Universitaria Bolivariana, Medellín, Colombia. Rev Colomb Obstet Ginecol 2006;57(4):264-270.

  17. Muñoz Molina L, Hernández Barbosa R. Retardo de crecimiento intrauterino (RCIU) y sus alteraciones bioquímicas. NOVA [seriado en línea] 2005;3(3):88-94. Disponible en: http://www.unicolmayor.edu.co/invest_nova/NOVA/ARTREVIS2_ 3.pdf

  18. Krammer M, Kahn S, Rozen R, Evans R, Platt RW, Chen MF. Vasculopathic and thrombophilic risk factors for spontaneous preterm birth. Int J Epidemiol 2009;38:715–723.

  19. Brenner B. Haemostatic changes in pregnancy. Thromb Res 2004;114(5-6):409-414.

  20. Cikot RJ, Steegers-Theunissen RP, Thomas C, Boo T, Merkus H, Steegers E. Longitudinal vitamin and homocysteine levels in normal pregnancy. Br J Nutr 2001;85(1):49-58.

  21. Murphy, M, Scott J, McPartlin JM, Fernandez- Ballart J. The pregnancy-related decrease in fasting plasma homocysteine is not explained by folic acid supplementation, hemodilution, or a decrease in albumin in a longitudinal study. Am J Clin Nutr 2002;76(3):614-619.

  22. Bermudez M, Briceño I, Gil F, Bernal J. Homocisteína y polimorfismos de cistationina β sintasa y metilentetrahidrofolato reductasa en población sana de Colombia. Colomb Med 2006;37(1):46-52.

  23. Milman N, Byg KE, Hvas AM, Bergholt T, Eriksen L. Erythrocyte folate, plasma folate and plasma homocysteine during normal pregnancy and postpartum: a longitudinal study comprising 404 Danish women. Eur J Haematol 2006;76(3):200-205.

  24. Lee SJ, Kim K, Namkoong S, Kim Ck, Kang YC, Lee H. Nitric Oxide Inhibition of Homocysteine-induced Human Endothelial Cell Apoptosis by Down-regulation of p53-dependent Noxa Expression through the Formation of S Nitrosohomocysteine. J Biol Chem 2005;280(7):5781-5788.

  25. Estellés A, Grancha S, Guilbert. J, Thinnes T, Chirivella M, España F, et al. Abnormal Expression of Plasminogen Activator Inhibitors in Patients with Gestational Trophoblastic Disease. Am J Pathol 1996;149(4):1229-1249.

  26. Maroney S, Cooley BC, Sood R, Weiler H, Mast AE. Combined tissue factor pathway inhibitor and thrombomodulin deficiency produces an augmented hypercoagulable state with tissuespecific fibrin deposition. J Thromb Haemost 2007;6:111–117.

  27. Choi JW, Pai. SH. Tissue plasminogen activator levels change with plasma fibrinogen concentrations during pregnancy. Ann Hematol 2002;81(11):611-615.

  28. Infante C, Rivard G,Guiget M,Gautier R. Thrombophilic Polymorphisms and Intrauterine Growth Restriction. Epidemiol 2005;16(3):281-287.

  29. Lentz SR. Mechanisms of thrombosis in hyperhomocysteinemia. Curr Opin Hematol 1998;5(5):343-349.

  30. Facco F, You W, Grobman W. Genetic thrombophilias and intrauterine growth restriction: a methanalysis. Obstet Gynecol 2009;113(6):1206-1216.

  31. Branch DW. Antiphospholipid antibodies and pregnancy: maternal implications. Semin perinatol 1990;14(2):439-446.

  32. Peeters LLH. Thrombophilia and fetal growth restriction. Eur J Obstet Gynecol Reprod Biol 2001;95:202-205.

  33. Kraus, F, Redline RW, Gersell DJ, Nelson M, Dicke M. Functional Anatomy. En Kraus FT, editor. Placental pathology. Washington D.C: AFIP; 2004. pp. 17-19.

  34. Shepard BL, Bonnar J. Uteroplacental Hemostasis in Intrauterine Growth Restriction. Semin Thromb Hemost 1999;25(5):443-445.

  35. Sikkema JM, Franxa A, Bruinsea HW, Van der Wijka NG, De Valkb HW, Nikkelsc PG. Placental Pathology in Early Onset Pre-eclampsia and Intra-uterine Growth Restriction in Women With and Without Thrombophilia. Plac 2002;23(4):337-342.

  36. Wramsby M,Sten-linder M, Bremme K. Primary habitual abortions are associated with high frequency of Factor V Leiden Mutation. Fertility and Sterility 2000;74(5):987-991.

  37. Locatelli A, Patane L, Ghidini A, Marinetti E, Zagarella A, Pezzullo JC, Cappellini “Pathology findings in preterm placentas of women with autoantibodies: a case-control study”. A. J Matern Fetal Neonatal Med 2002;11(5):339-44.

  38. Rodger M, Betancourt1 MT, Clark P, Lindqvist PG, Dizon- Townson D, Said J, et al. The Association of Factor V Leiden and Prothrombin Gene Mutation and Placenta-Mediated Pregnancy Complications: A Systematic Review and Metaanalysis of Prospective Cohort Studies. Plos Medicine [seriado en linea]. 2010;7(6):1-12. Disponible en: http://www.ncbi.nlm. nih.gov/pmc/articles/PMC2885985/?tool=pubmed.

  39. Kraus F, Redline RW, Gersell DJ, Nelson M, Dicke M. Maternal Thrombophilias. En: Kraus F.T, editor. Placental pathology. Washington D.C: AFIP; 2004. pp. 34-36.

  40. Raspollini MR, Oliva E, Roberts DJ. Placental histopathologic features in patients with thrombophilic Mutations. J Matern Fetal Neonatal Med 2007;20(2):113–123.

  41. Vora S, Shetty S, Khare M, Ghosh K. Placental histomorphology in unexplained fetal loss with thrombophilia. Indian J Med Res 2009;129:144-149.

  42. Kinsler W, Prrasad V Ananith C. The effect of maternal thrombophilia on placental abruption: Histologic correlates. J Matern Fetal Neonatal Med 2009;22(3):243–248.

  43. Tranquilli A, Giannubiloa S, Dell’Uomoa B, Grandone E. Adverse pregnancy outcomes are associated with multiple maternal thrombophilic factors. Eur J Obstet Gynecol Reprod Biol 2004;117:144–147.

  44. Ariel I, Anteby E, Hamani Y, Redline R. Placental Pathology in Fetal Thrombophilia. Hum Pathol 2004;35(6):729-733.

  45. Toos A,Goddijn W, Wouters M, Molen E, Spujibroek M, Steegers-Theumissen R. Hyperhomocysteinemia: a risk factor for placental abruption or infarction European Journal of Obstetrics & Gynecology and Reproductive Biology 1996;66:23-29.

  46. Mousa HA, Alfirevic Z. Do placental lesions reflect thrombophilia state in women with adverse pregnancy outcome? Hum Reprod 2000;15(8):1830-1833.

  47. Shimchen MJ, Ofir K, Moran O, Kedem A, Sivan E, Schiff E. Thrombophilic risk factors for placental stillbirth. Eur J Obstet Gynecol Reprod Biol 2010;153:160-164.

  48. Beverly B. Rogers BB, Momirova V, Dizon-Townson D, Wenstrom K, Samuels P, et al. Avascular villi increase syncytial knots and hypervascular villi are associated with pregnancies complicated by factor V leiden mutation. Pediatr Dev Pathol 2010;15(5):341-347.

  49. Kisst W, Janssen NG, Kalk JJ, Hague WM, Dekker GA, de Vries JL. Thrombophilias and adverse pregnancy outcome: A confounded problem. Thromb Haemost 2008;99(1):77- 85.

  50. Redline, R. Thrombophilia and Placental Pathology. Clin Obstet Gynecol 2006;49(4):885-894.

  51. Waters B, Ashikaga T. Significance of Perivillous Fibrinoid Deposition in Uterine Evacuation Specimens. Am J Surg Pathol 2006;30(6):760-765.

  52. Bjor O, Vatten L, Romundstad PA, Karumanchi A, Eskild A. Angiogenic Factors in Maternal Circulation and the Risk of Severe Fetal Growth Restriction. Am J Epidemiol 2011;173:630–639.

  53. Guller, S. Role of the syncytium in placenta-mediated complications of preeclampsia.Thromb Res 2009;124(4):389– 392.

  54. Watanabe H, Kabeyama K, Sugiyama T Fukuoka H. A Review of Inadequate and Excessive Weight Gain in Pregnancy. Curr Womens Health Rev 2009;5(4):186-92.

  55. Cuartas, A. Retardo del Crecimiento Intrauterino. Iatreia 1995;8(1):18-25.




2020     |     www.medigraphic.com